Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLN 
Silence Therapeutics PLC (SLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: SLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33.8
1 Year Target Price $33.8
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 157.98% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 340.08M USD | Price to earnings Ratio - | 1Y Target Price 33.8 |
Price to earnings Ratio - | 1Y Target Price 33.8 | ||
Volume (30-day avg) 7 | Beta 1.38 | 52 Weeks Range 1.97 - 18.32 | Updated Date 10/23/2025 |
52 Weeks Range 1.97 - 18.32 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -291.24% | Operating Margin (TTM) -9048.21% |
Management Effectiveness
Return on Assets (TTM) -22.25% | Return on Equity (TTM) -66.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68993679 | Price to Sales(TTM) 12.52 |
Enterprise Value 68993679 | Price to Sales(TTM) 12.52 | ||
Enterprise Value to Revenue 2.54 | Enterprise Value to EBITDA -5.78 | Shares Outstanding 47233949 | Shares Floating 74747724 |
Shares Outstanding 47233949 | Shares Floating 74747724 | ||
Percent Insiders 24.38 | Percent Institutions 42.23 |
Upturn AI SWOT
Silence Therapeutics PLC
Company Overview
History and Background
Silence Therapeutics PLC was founded in 1994. It focuses on the discovery and development of novel gene silencing therapies based on messenger RNA (mRNA) interference.
Core Business Areas
- RNA Interference (RNAi) Therapeutics: Silence Therapeutics develops siRNA molecules designed to selectively silence disease-causing genes within liver cells.
- GalNAc Conjugation: The company utilizes its proprietary GalNAc conjugation technology to enhance the delivery of siRNA therapeutics to hepatocytes.
- Discovery and Development: Silence Therapeutics engages in the discovery and early development of novel mRNAi therapeutic candidates.
Leadership and Structure
Craig Tooman is the CEO. The company has a board of directors and various management teams overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Zilebesiran: An investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension. Phase 3 development. Competitors include existing hypertension medications and novel therapies from Alnylam, Novartis, and Roche.
- SLN124: An investigational RNAi therapeutic targeting TMPRSS6 for the treatment of anemia. Phase 1 clinical trials have been conducted. Competing treatment options include traditional therapies for anemia and innovative therapies from companies like Protagonist Therapeutics.
- mRNAi GOLD Platform: Proprietary technology for discovering and developing RNAi therapeutics. No direct market share, but provides a technological advantage in developing future pipeline products.
Market Dynamics
Industry Overview
The RNAi therapeutics market is growing rapidly, driven by advances in delivery technologies and the potential to address previously untreatable diseases.
Positioning
Silence Therapeutics is a key player in the RNAi therapeutics space, particularly focused on liver-targeted therapies. It has a strong technology platform and a growing pipeline of drug candidates.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics is estimated to reach billions of dollars. Silence Therapeutics is positioned to capture a significant share by developing innovative therapies for high-need conditions such as hypertension and anemia.
Upturn SWOT Analysis
Strengths
- Proprietary mRNAi GOLD platform
- Strong expertise in liver-targeted delivery
- Growing pipeline of clinical-stage drug candidates
- Strategic partnerships with leading pharmaceutical companies
Weaknesses
- Limited commercial infrastructure
- Reliance on partnerships for late-stage development and commercialization
- Cash burn rate
- Clinical Trial Risks
Opportunities
- Expanding into new therapeutic areas
- Developing next-generation RNAi technologies
- Securing additional partnerships
- Regulatory approval of key pipeline assets
Threats
- Competition from other RNAi therapeutics companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ALNY
- VIR
- MRNA
Competitive Landscape
Silence Therapeutics competes with larger and more established pharmaceutical companies in the RNAi therapeutics space. Its competitive advantages lie in its proprietary technology platform and expertise in liver-targeted delivery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline and the signing of strategic partnerships.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and continued partnerships.
Recent Initiatives: Recent initiatives include advancing Zilebesiran into phase 3, progressing SLN124 through clinical trials, and expanding its mRNAi GOLD platform.
Summary
Silence Therapeutics is a biotech company focused on RNAi therapeutics, with a promising pipeline, particularly zilebesiran. The company is reliant on clinical trial success, partnerships and faces competition from other companies. The lack of profitability needs to be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is not real-time and should be verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Silence Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-08 | President, CEO & Executive Director Mr. Craig A. Tooman M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | |
Full time employees 116 | |||
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.